Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP002013)
SBP Name
DARPin MP0250
Synonyms
MP-0250; MP-0250; anti-VEGFHGF DARPins (cancer), Molecular Partners; designed ankyrin repeat proteins (cancer), Molecular Partners
Molecular Weight 62.4 kDa
Thermal Denaturation TEMP 90 ℃
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Expression System Escherichia coli
Selection Method Phage display and Ribosome display
Highest Status Phase II
Sequence Length 603
Protein Scaffold Information of This SBP
Scaffold ID PS027
Scaffold Info
[1] , [2] , [3]
Scaffold Name DARPin
Scaffold Class Non-Antibody
Fold Type Alpha-Helices + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Vascular endothelial growth factor A
BTS Info
Antagonist Multiple myeloma [ICD-11: 2A83.Y]; Non-small cell lung cancer [ICD-11: 2C25.Y]; Solid tumour/cancer [ICD-11: 2A00-2F9Z] Kd: <1 nM Molecular Partners; Allergan [1] , [2] , [3]
Hepatocyte growth factor
BTS Info
Antagonist Multiple myeloma [ICD-11: 2A83.Y]; Non-small cell lung cancer [ICD-11: 2C25.Y]; Solid tumour/cancer [ICD-11: 2A00-2F9Z] Kd: <1 nM Molecular Partners; Allergan [1] , [2] , [3]
Clinical Trial Information of This SBP
NCT02194426 Click to show the Detail
Indication Advanced Solid Tumours
Phase Phase I; Phase II
Title A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours
Status Completed
Sponsor Molecular Partners
NCT03136653 Click to show the Detail
Indication Multiple Myeloma
Phase Phase II
Title A Phase II Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
Status Active, not recruiting
Sponsor Molecular Partners
NCT03418532 Click to show the Detail
Indication Non-Small Cell Lung Cancer (NSCLC)
Phase Phase I; Phase II
Title A Phase Ib/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib
Status Terminated
Sponsor Molecular Partners
References
1 DARPins: Promising Scaffolds for Theranostics. Acta Naturae. Oct-Dec 2019;11(4):42-53.
2 MP0250, a VEGF and HGF neutralizing DARPin ? molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models. Oncotarget. 2017 Oct 11;8(58):98371-98383.
3 Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. Curr Opin Pharmacol . 2020 Apr;51:93-101.